Key Highlights

  • Avacta Group PLC (LSE:AVCT) is drawing attention ahead of two poster presentations at the ESMO 2026 Congress in Madrid, which runs from 23 to 27 October.
  • New progression-free survival and imaging data for lead drug AVA6000 in salivary gland cancer will be shown on 26 October.
  • The company raised about £12.5 million at 68 pence per share earlier this month, and four directors subscribed for around £660,000.
  • The new money extends the cash runway into the second quarter of 2027 and covers a convertible bond instalment due on 20 October.

Why Avacta (LSE:AVCT) Is in Focus Today

Avacta Group PLC (LSE:AVCT), the clinical-stage oncology company built around its tumour-targeted pre|CISION drug platform, has moved back into investors' view in the week to 16 October 2026. The main trigger was an update on 14 October confirming that Avacta will present two posters at the European Society for Medical Oncology congress later this month. ESMO is one of the most important events in the cancer drug calendar. For a small biotech, a presence there can sharpen market interest in its data and attract potential partners.

The stock has also been working through the effects of a fundraise completed at the start of October. After the placing was priced at a modest discount, the shares have traded in the mid to high 60 pence range. The most recent session showed a small gain to around 66 to 67 pence, giving a market value of roughly £290 million. With a high-profile data event less than two weeks away, Avacta (LSE:AVCT) has become one of the more actively discussed healthcare names on AIM, and social media chatter among private investors has picked up accordingly.

What Will Be Presented at ESMO 2026

The first poster covers AVA6000, also known as faridoxorubicin, in patients with salivary gland cancers. The drug is a modified form of the established chemotherapy doxorubicin. It is designed to stay inactive until it meets an enzyme called fibroblast activation protein, which is highly concentrated in the tissue around many solid tumours. The poster will include progression-free survival data from an expansion cohort plus FAPI-PET imaging results, and it is scheduled for the lunchtime session on Monday 26 October.

The second poster focuses on AVA6103, the company's second pre|CISION candidate, which carries a different payload based on exatecan. It is a trials-in-progress presentation describing the design of the Phase 1 FOCUS-01 study, along with updated preclinical findings. First efficacy data from that trial are expected in the first half of 2027.

Recent Developments: Funding and Clinical Progress

The October fundraise was Avacta's third equity raise of 2026, following about £10 million in March and around £9 million in June. The latest placing and subscription raised roughly £12.5 million at 68 pence per share, about 5.6 percent below the prior closing price, and added just under 4 percent to the share count. Board members including the chair took part, which market commentary generally reads as a sign of insider confidence. Around £2.5 million of the proceeds is set aside to repay, in cash, a quarterly convertible bond instalment due on 20 October.

Clinically, Avacta has made steady progress this year. In June it said the US Food and Drug Administration had agreed key elements of a pivotal trial design for AVA6000, including a regulatory path that draws on Phase 1b data. In September it reported what it called clinical proof of mechanism for the pre|CISION platform, showing the drug payload being released preferentially in tumour tissue. The company is actively seeking a commercial partner for AVA6000.

Financial Backdrop

Interim results for the six months to 30 June 2026 showed the typical profile of a development-stage biotech. Revenue from continuing operations was negligible. Research spending rose to nearly £9.7 million, and the operating loss was about £13.9 million. Cash fell to about £10.6 million by the end of August before the latest raise, and net assets were thin. The diagnostics division is classified as held for sale as the group concentrates fully on therapeutics. The outstanding convertible bond remains a meaningful obligation, although recent instalments have been settled in cash rather than in shares, which limits dilution.

Sector and Market Context

Avacta is a constituent of the FTSE AIM All-Share index, in a UK small-cap biotech sector where funding has been scarce. Appetite has improved somewhat as large drugmakers keep licensing targeted oncology assets such as antibody-drug conjugates, and Avacta pitches its platform as a simpler alternative.

What Investors Are Watching Next

The immediate catalyst is the ESMO presentation on 26 October, where progression-free survival figures in salivary gland cancer will be closely examined. Next is the convertible bond payment on 20 October. Further ahead, Avacta has guided to candidate selection data for its dual-payload programme AVA6207 in the fourth quarter of 2026 and first efficacy readouts from AVA6103 in the first half of 2027. Any news on a partnership for AVA6000 or on the timing of a pivotal study would be a significant event for Avacta Group (LSE:AVCT).

Risks to Consider

With runway only into the second quarter of 2027, further dilutive funding is likely. Small-cohort data can disappoint, partnering may take longer than hoped, and the convertible bond adds pressure.